The valuation gap versus peers is substantial: Stryker's EV/EBITDA of 23.3x compares to Boston Scientific's 15.7x and Zimmer Biomet's 10.5x. This premium appears justified by Stryker's consistently higher gross margins (68.3% vs. peer average ~65%) and stronger revenue acceleration (9.4% in 2026Q2). However, the PEG ratio of 2.70 implies that the market is pricing in growth that may already be reflected in consensus estimates, leaving limited room for multiple expansion. Investors should monitor whether the forward P/E of 22.5x can be sustained if growth decelerates to single digits.

The gross margin expansion is a genuine positive, likely driven by product mix and cost efficiencies, but the operating margin jump from 15.5% in 2026Q1 to 25.2% in 2026Q2 is too abrupt to be purely operational. The net margin volatility—ranging from 8.5% in 2024Q4 to 19.4% in 2026Q2—indicates that tax benefits or one-time gains are inflating recent profitability. Adjusted operating margin, excluding non-recurring items, may be closer to 20-22%, still strong but less spectacular. Investors should focus on the sustainability of gross margin expansion rather than quarterly net margin spikes.

Stryker's ROIC has been volatile, ranging from 2.0% to 4.2% over the last ten quarters, with the recent uptick driven by margin expansion and a lower capital base as debt is repaid. However, the absolute level is modest for a company with such high gross margins, indicating that the heavy goodwill from acquisitions ($25.3B) is diluting returns on invested capital. The improvement in 2026Q2 is encouraging, but ROIC needs to consistently exceed 5% to justify the premium valuation. The gap between ROIC and ROE (5.4% in 2026Q2) suggests leverage is amplifying equity returns, but the underlying capital efficiency remains subpar.

The CCC has been consistently above 200 days for the past year, with DIO reaching 238 days in 2026Q2, a significant increase from 189 days in 2024Q4. This suggests that Stryker is accumulating inventory, possibly in anticipation of demand or due to supply chain issues, but it ties up cash and increases the risk of obsolescence. DSO has remained stable around 50-60 days, indicating no deterioration in receivables collection. The efficiency of asset turnover is low at 0.14x, reflecting the heavy goodwill on the balance sheet, which does not generate revenue directly. Management should focus on inventory reduction to improve cash conversion.

Stryker has been deleveraging, with total debt declining from $17.5B to $14.2B over the past year, which is a positive trend. However, the D/EBITDA ratio of 9.07x is still elevated compared to peers like Medtronic at 3.5x, indicating that Stryker carries more debt relative to its earnings. Interest coverage of 6.74x is adequate but not robust, and it could be strained if EBITDA declines or interest rates rise. The company's ability to service debt appears manageable, but the high leverage relative to peers suggests limited financial flexibility for additional large acquisitions without further equity issuance.

The liquidity position has strengthened significantly, with the current ratio now above 2.0, indicating that Stryker can comfortably cover short-term obligations. The quick ratio of 1.33, excluding inventory, still shows adequate coverage, though inventory dependence is moderate. The increase in cash to $3.4B provides a buffer, but it is modest relative to the $14.2B in total debt. Under a severe stress scenario, such as a prolonged downturn in elective procedures, Stryker's liquidity would likely hold, but the high inventory levels could become a drag if demand falters. Overall, the liquidity position appears healthy.

Stryker commands a significant valuation premium over peers, which is supported by its superior gross margins and revenue growth. However, its ROE of 5.4% is below the peer average of about 10%, indicating that the company is not generating equity returns commensurate with its premium valuation. This discrepancy may be due to the large goodwill base and lower asset turnover. The gap in ROE is structural, as Stryker's heavy M&A activity inflates the equity base without proportional earnings. Investors should compare Stryker on an EV/EBITDA basis, where the premium is more justified given its EBITDA margins, rather than on P/E or ROE.